NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

STATUS

Recruiting
End date

Dec 31, 2026
participants needed

24
sponsor

M.D. Anderson Cancer Center

Send

Updated on 19 February 2024

See if I qualify

cancer

platelet count

metastasis

gemcitabine

neutrophil count

paclitaxel

oxaliplatin

adenocarcinoma

irinotecan

capecitabine

fluorouracil

leucovorin

endoscopic ultrasound

pancreatic adenocarcinoma

celiac disease

resectable pancreatic cancer

pancreatic cancer

cisplatin

Summary

The purpose of this Phase I study is to determine the recommended phase 2 dose (RP2D) and safety profile of NBTXR3 activated by radiation therapy for the treatment of patients with pancreatic cancer that has spread to nearby tissues or lymph nodes (locally advanced) or may be able to be removed by surgery (borderline-resectable). NBTXR3 is a drug that when activated by radiation therapy, may cause targeted destruction of cancer cells. Radiation therapy uses high energy to kill cancer cells and shrink tumors. Giving NBTXR3 followed by radiation therapy may work better to treat locally advanced or borderline-resectable pancreatic cancer compared to radiation therapy alone.

Description

PRIMARY OBJECTIVE:

I. To determine the recommended phase II dose (RP2D) of hafnium oxide nanoparticles NBTXR3 (NBTXR3) activated by radiation therapy (RT) (hereafter referred to R3/RT).

SECONDARY OBJECTIVES:

I. To evaluate the anti-tumor response of R3/RT. II. To evaluate the safety and feasibility of R3/RT. III. To evaluate time-to-event outcomes.

EXPLORATORY OBJECTIVES:

I. To evaluate the body kinetic profile of intratumorally injected NBTXR3. II. To evaluate time to event outcomes for subjects with clinical staging of locally advanced, unresectable disease.

III. To evaluate resectability conversion rates. IV. To evaluate surgical outcomes in subjects who undergo surgery after radiation therapy.

V. To associate radiomic measurements with outcomes. VI. To evaluate biomarkers of response in subjects treated with R3/RT.

OUTLINE: This is a dose-escalation study of NBTXR3.

Patients receive NBTXR3 intratumorally (IT) on day 1. Patients then undergo 15 fractions of intensity modulated radiation therapy (IMRT) between days 15-43 in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 1 month and then every 3 months for up to 1 year.

Details

Condition	Locally Advanced Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
Age	18-100 years
Treatment	Radiation Therapy, Hafnium Oxide-containing Nanoparticles NBTXR3
Clinical Study Identifier	NCT04484909
Sponsor	M.D. Anderson Cancer Center
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Signed informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study
	Biopsy proven ductal adenocarcinoma of the pancreas as defined by the following
	Borderline resectable pancreatic adenocarcinoma (BRPC) has no aortic involvement with at least ONE of the following features
	Superior mesenteric vein (SMV) or portal vein (PV) with a tumor interface of >= 180 degrees OR short segment occlusion amenable to reconstruction
	Superior mesenteric artery (SMA) or celiac axis (CA) with a tumor interface of < 180 degrees
	Any degree of hepatic artery interface this is amenable to reconstruction
	Locally advanced pancreatic adenocarcinoma (LAPC) has at least ONE of the following features
	Occlusion of the SMV or PV that is not amenable to reconstruction
	Tumor interface of the SMA or CA >= 180 degrees
	Involvement of the hepatic artery that is not amenable to reconstruction
	Aortic involvement
	Has had a 4-month course (+/- 2-months) of chemotherapy for PDAC without radiographic evidence of metastatic disease. Following chemotherapy regimens are allowed
	Gemcitabine/nab-paclitaxel
	Gemcitabine/capecitabine
	Gemcitabine/cisplatin
	Gemcitabine
	Leucovorin calcium, fluorouracil and oxaliplatin (FOLFOX)
	Fluorouracil, irinotecan, leucovorin and oxaliplatin (FOLFIRINOX)
	Amenable to undergo the endoscopic ultrasound guided injection of NBTXR3 as per investigator or treating physician
	Has a target lesion in the pancreas that is identifiable on cross sectional imaging by repeated measurements (via Response Evaluation Criteria for Solid Tumors [RECIST v1.1]) at the same anatomical location
	Nodal disease only is not allowed
	Eastern Cooperative Oncology Group (ECOG) performance status 0-1
	Hemoglobin >= 8.0 g/dL (at screening)
	Absolute neutrophil count (ANC) >= 1,500/mm^3 (at screening)
	Platelet count >= 100,000/mm^3 (at screening)
	Creatinine =< 1.5 x upper limit of normal (ULN) (at screening)
	Total bilirubin =< 2.0 mg/dL (at screening)
	Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) (at screening)
	Negative pregnancy test =< 7 days prior to NBTXR3 injection in all females of child-bearing potential
	If participant has a history of prior duodenal or biliar plastic stent, it should be replaced with a metal stent >= 1 weeks prior to study day 1
Exclusion Criteria
	Prior radiation therapy to the upper abdomen
	Prior surgical resection of pancreatic tumor
	Diagnosis other than pancreatic ductal adenocarcinoma. All other histologic types (i.e., adenosquamous, cystadenocarcinoma, etc.) are not eligible to participate on this study
	LAPC or BRPC with radiographic evidence of metastasis at screening
	Receiving any approved or investigational anti-neoplastic agent other than the chemotherapies specified in this protocol (i.e., chemotherapies listed above)
	Known uncontrolled (grade >= 2) or active gastric or duodenal ulcer disease within 30 days of enrollment
	Known contraindication to iodine-based or gadolinium-based intravenous (IV) contrast
	Active malignancy, in addition to pancreatic cancer, with the exception of basal cell carcinoma of the skin definitively treated and relapse free within at least 1 year since diagnosis
	Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes, second or third degree atrioventricular heart block without a permanent pacemaker in place)
	Class III or IV congestive heart failure as defined by the New York Heart Association functional classification system < 6 months prior to screening
	Known active, uncontrolled (high viral load) human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection
	Patients who have been vaccinated for hepatitis B and do not have a history of infection are eligible
	Female patients who are pregnant or breastfeeding
	Women of child-bearing potential and their male partners who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period. Acceptable methods of contraception are those that, alone or in combination, result in a failure rate of < 1% per year when used consistently and correctly
	Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

endoscopic ultrasound

pancreatic adenocarcinoma

celiac disease

resectable pancreatic cancer

pancreatic cancer

cisplatin

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer